KeViRx Selected as Part of BLUE KNIGHT™ Collaboration for Global Health Preparedness
Charlottesville, Virginia – February 2022
KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services.
Blue Knight is a collaborative program designed to anticipate and respond to global health security threats. Blue Knight provides a scientific and technological ecosystem for innovative, early stage startup companies to develop technologies that are strategically aligned with global health interests. KeViRx was selected for this program based on its platform small molecule technology, KVX-053, which displays efficacy in preclinical models of ovarian cancer, acute myeloid leukemia and acute lung injury. As a Blue Knight company with a footprint at JLABS @ Washington, DC, KeViRx will benefit from dedicated mentorship and unique benefits from BARDA, in addition to access to the Johnson & Johnson Innovation extensive global network of innovators for critical insights centering on KVX-053 development.
“KeViRx is honored to be selected to be a Blue Knight company and we are excited to be working with the Blue Knight program. We are optimistic that the program will help advance our KVX-053 platform for global health applications in the present and the future,” said Dr. John S. Lazo, who serves as KeViRx’s Chief Scientific Officer.
About KeViRx, Inc.
KeViRx, Inc. was founded in 2016 in Charlottesville, VA and is a privately-held biotechnology company focusing on small molecule-based drug discovery. KeViRx’s platform technology, KVX-053, has efficacy in multiple disease models including cancer and acute lung injury.
For further information, please visit www.KeViRx.com.